Group 1 - The company was asked about its third-quarter capacity utilization and the price trends of its main products on an investor interaction platform [2] - The company indicated that details regarding its third-quarter performance will be disclosed in an announcement scheduled for October 28, 2025 [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.02% on October 21, with Bioworks leading the drop. Meanwhile, the Shanghai Composite Index rose by 1.36% and the Shenzhen Component Index increased by 2.06% [1]. Group 1: Market Performance - The animal health sector's performance was mixed, with individual stocks showing varying degrees of increase and decrease. Notably, the top gainers included: - Driving Force (4.50% increase) [1] - Dayu Biological (3.46% increase) [1] - Yongshun Biological (2.06% increase) [1] - Conversely, Bioworks saw a decline of 2.10%, leading the losses in the sector [2]. Group 2: Trading Volume and Capital Flow - The trading volume for the animal health sector indicated a net outflow of 151 million yuan from institutional investors, while retail investors saw a net inflow of 116 million yuan [2]. - The capital flow for individual stocks showed significant movements, with: - Key stock, Bioworks, experiencing a net outflow of 6.46 million yuan from institutional investors [3]. - Retail investors contributed a net inflow of 7.59 million yuan to Zhongmu Co. [3]. Group 3: Individual Stock Analysis - The following stocks had notable capital flows: - KQ Biological had a net inflow of 1.83 million yuan from institutional investors [3]. - ST Green Health faced a net outflow of 4.37 million yuan from institutional investors [3]. - The stock of Rui Pu Biological saw a net inflow of 17.22 million yuan from retail investors despite a net outflow from institutional investors [3].

证券代码：300871 证券简称：回盛生物 公告编号：2025-097 武汉回盛生物科技股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开的第三届董事会第二十二次会议和第三届监事会第十四次会议，分别审 议通过了《关于公司及子公司 2025 年度向金融机构申请综合授信额度并由公 司实际控制人提供担保暨关联交易的议案》，同意公司及子公司 2025 年度向 金融机构申请总金额不超过人民币 10 亿元的综合授信，并由公司实际控制人 张卫元先生、余姣娥女士无偿提供担保，有效期自董事会审议通过之日起 1 年；同意公司为子公司湖北回盛生物科技有限公司（以下简称"湖北回盛"）、 武汉新华星动物保健连锁服务有限公司（以下简称"武汉新华星"）向银行申 请授信提供担保，合计额度不超过人民币 4.00 亿元，子公司湖北回盛为公司 申请银行授信提供担保，额度不超过人民币 6.00 亿元。具体内容详见公司于 2025 年 4 月 29 日在巨 ...

Market Overview - The animal health sector increased by 0.81% on October 20, with Xianfeng Holdings leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Xianfeng Holdings (002141) closed at 4.06, up 5.45% with a trading volume of 588,700 shares and a turnover of 237 million yuan [1] - Other notable stocks included ST Lvkang (002868) at 28.36, up 5.00%, and Biological Shares (600201) at 10.95, up 1.48% [1] - The overall trading volume and turnover for the animal health sector were significant, indicating active market participation [1] Capital Flow - The animal health sector saw a net inflow of 31.5863 million yuan from institutional investors, while retail investors experienced a net outflow of 10.9434 million yuan [2] - The main capital inflow was primarily directed towards Xianfeng Holdings, which had a net inflow of 28.5381 million yuan [3] - Conversely, stocks like Shunlian Biological (688088) and ST Lvkang experienced net outflows from retail investors, indicating a shift in investor sentiment [3]

Core Insights - The animal health sector experienced a decline of 0.28% on October 17, with Ruipu Biotech leading the drop [1][2] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Shenyuan Biological (688088) saw a significant increase of 10.65%, closing at 11.43 with a trading volume of 319,600 shares and a turnover of 368 million yuan [1] - Other notable gainers included Yongshun Biological (920729) with a rise of 2.94% and Xianfeng Holdings (002141) with an increase of 1.85% [1] - Conversely, Ruipu Biotech (300119) fell by 2.47%, closing at 21.69 with a trading volume of 109,100 shares and a turnover of 239 million yuan [2] Capital Flow - The animal health sector saw a net inflow of 33.17 million yuan from institutional investors, while retail investors experienced a net outflow of 37.18 million yuan [2][3] - Shenyuan Biological had a net inflow of 76.52 million yuan from institutional investors, representing 20.82% of its trading volume [3] - In contrast, other companies like XD Plai Ke (603566) and Huayi Biological (603718) faced significant net outflows from both institutional and retail investors [3]

Core Viewpoint - The company Huisheng Biological (300871) announced the appointment of Ms. Li Xing as the representative for securities affairs [1] Group 1 - The appointment of Ms. Li Xing is aimed at enhancing the company's communication and transparency with investors [1]

Core Points - Wuhan Huisheng Biotechnology Co., Ltd. has revised its company articles to enhance governance and protect the rights of stakeholders [1][2] - The company was registered on July 27, 2020, and went public on August 24, 2020, with a registered capital of RMB 202.332557 million [1] - The revision includes detailed rules on share management, shareholder rights and obligations, board structure, and management responsibilities [2] Share Management - The total number of shares is 202.332557 million, all of which are ordinary shares [1] - The company has established rules for share issuance, reduction, repurchase, and transfer, ensuring equal rights for the same class of shares [1] - Specific restrictions on share transfer are in place, such as a one-year lock-up period for shares issued before the public offering [1] Shareholder and Shareholder Meeting - The rights and obligations of shareholders, as well as the responsibilities of controlling shareholders and actual controllers, are clearly defined [2] - Shareholders have rights to dividends and participation in shareholder meetings, while also being obligated to comply with the articles and pay share capital [2] - The shareholder meeting has decision-making authority on major company matters, including electing directors and approving profit distribution [2] Board of Directors - The board consists of five directors, including two independent directors and one employee director [2] - The board is accountable to the shareholder meeting and has various powers, including convening meetings and executing resolutions [2] - Detailed responsibilities and operations for independent directors and board committees are outlined [2] Senior Management - The company appoints one general manager and several deputy managers, with clear qualifications and responsibilities for senior management [2] - The articles also cover financial accounting, profit distribution, auditing, and procedures for corporate actions such as mergers and dissolutions [2] Conclusion - The revision of the company articles is a significant step for Huisheng Biotechnology to adapt to its development and market changes, aiming to improve governance and ensure sustainable operations [2]

Group 1 - The company, Huisheng Biological, announced the convening of its third temporary board meeting for the fourth session on October 16, 2025, to discuss the election of committee members [1] - For the fiscal year 2024, the revenue composition of Huisheng Biological is 93.02% from veterinary raw materials and formulations, with the remaining 6.98% from other sources [1] - As of the report date, Huisheng Biological has a market capitalization of 4.2 billion yuan [1]

武汉回盛生物科技股份有限公司 章 程 （本章程经 2025 年第三次临时股东大会审议通过后生效） 二〇二五年九月 | - | . | 7 | 1 | | --- | --- | --- | --- | | 2 | | | | | | | | | | 武汉回盛生物科技股份有限公司 章程 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和行为， 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证 券法》（以下简称《证券法》）、中国证券监督管理委员会（以下简称"中国证 监会"）颁布的《上市公司章程指引》和其他有关规定，制订本章程。 第二条 武汉回盛生物科技股份有限公司系依照《公司法》和其他有关规定成立 的股份有限公司（以下简称"公司"或"本公司"）。 公司是武汉回盛生物科技有限公司以整体变更的方式设立的股份公司；在湖北省 武汉市市场监督管理局注册登记，取得营业执照，统一社会信用代码： 9142011273354032X9。 第三条 公司于 2020 年 7 月 27 日经中国证券监督管理委员会注册，首次向社会 公众发行人民币普通股 2,770 万股，于 2020 年 ...

证券代码：300871 证券简称：回盛生物 公告编号：2025-094 武汉回盛生物科技股份有限公司 2025年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （2）网络投票时间：2025年10月16日，其中，通过深圳证券交易所交易 系统进行网络投票的具体时间为：2025年10月16日 9:15-9:25、9:30-11:30和 13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为2025年10 月16日 9:15-15:00。 2、现场会议召开地点：湖北省武汉市武昌区中华路1号306会议室。 3、会议召开方式：本次股东大会采取现场表决与网络投票相结合的方式 召开。同一表决权只能选择现场投票、深圳证券交易所交易系统投票、互联网 投票系统中的一种表决方式，同一表决权出现重复投票表决的，以第一次投票 1、会议召开时间： （1）现场会议召开时间：2025年10月16日（星期四）14:00 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议； 3、本次股东大会审议的议案 ...